These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 23812823)

  • 1. Neuroprotection in glaucoma.
    Tamm ER; Grehn F; Pfeiffer N
    Cell Tissue Res; 2013 Aug; 353(2):201-3. PubMed ID: 23812823
    [No Abstract]   [Full Text] [Related]  

  • 2. Autocrine and paracrine interactions and neuroprotection in glaucoma.
    Weber AJ
    Cell Tissue Res; 2013 Aug; 353(2):219-30. PubMed ID: 23358746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retinal ganglion cells and neuroprotection for glaucoma.
    Levin LA
    Surv Ophthalmol; 2003 Apr; 48 Suppl 1():S21-4. PubMed ID: 12852431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rasagiline-induced delay of retinal ganglion cell death in experimental glaucoma in rats.
    Levkovitch-Verbin H; Vander S; Melamed S
    J Glaucoma; 2011; 20(5):273-7. PubMed ID: 20577110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroprotection in glaucoma: recent and future directions.
    Danesh-Meyer HV
    Curr Opin Ophthalmol; 2011 Mar; 22(2):78-86. PubMed ID: 21252670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Neuroprotection in glaucoma. What is the current status?].
    Haefliger IO; Pellanda N; Fleischhauer JC; Gekkieva M; Flammer J
    Ophthalmologe; 2001 Jun; 98(6):564-7. PubMed ID: 11450482
    [No Abstract]   [Full Text] [Related]  

  • 7. Neuroprotection of medical IOP-lowering therapy.
    Pfeiffer N; Lamparter J; Gericke A; Grus FH; Hoffmann EM; Wahl J
    Cell Tissue Res; 2013 Aug; 353(2):245-51. PubMed ID: 23836043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glaucoma: Focus on mitochondria in relation to pathogenesis and neuroprotection.
    Osborne NN; Núñez-Álvarez C; Joglar B; Del Olmo-Aguado S
    Eur J Pharmacol; 2016 Sep; 787():127-33. PubMed ID: 27090928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined effect of brain-derived neurotrophic factor and LINGO-1 fusion protein on long-term survival of retinal ganglion cells in chronic glaucoma.
    Fu QL; Li X; Yip HK; Shao Z; Wu W; Mi S; So KF
    Neuroscience; 2009 Aug; 162(2):375-82. PubMed ID: 19422885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VEGF-A is necessary and sufficient for retinal neuroprotection in models of experimental glaucoma.
    Foxton RH; Finkelstein A; Vijay S; Dahlmann-Noor A; Khaw PT; Morgan JE; Shima DT; Ng YS
    Am J Pathol; 2013 Apr; 182(4):1379-90. PubMed ID: 23416159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroprotection by sodium channel blockade with phenytoin in an experimental model of glaucoma.
    Hains BC; Waxman SG
    Invest Ophthalmol Vis Sci; 2005 Nov; 46(11):4164-9. PubMed ID: 16249495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Introductory comments on neuroprotection.
    Kaufman PL; Gabelt BT; Cynader M
    Surv Ophthalmol; 1999 Jun; 43 Suppl 1():S89-90. PubMed ID: 10416751
    [No Abstract]   [Full Text] [Related]  

  • 13. Neuroprotection: is it already applicable to glaucoma therapy?
    Ritch R
    Curr Opin Ophthalmol; 2000 Apr; 11(2):78-84. PubMed ID: 10848224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potential of neuroprotection in glaucoma treatment.
    Osborne NN; Chidlow G; Nash MS; Wood JP
    Curr Opin Ophthalmol; 1999 Apr; 10(2):82-92. PubMed ID: 10537768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent clinical findings with memantine should not mean that the idea of neuroprotection in glaucoma is abandoned.
    Osborne NN
    Acta Ophthalmol; 2009 Jun; 87(4):450-4. PubMed ID: 19141144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In glaucoma, should enthusiasm about neuroprotection be tempered by the experience obtained in other neurodegenerative disorders?
    Haefliger IO; Fleischhauer JC; Flammer J
    Eye (Lond); 2000 Jun; 14 ( Pt 3B)():464-72. PubMed ID: 11026975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular and cell-based approaches for neuroprotection in glaucoma.
    Lebrun-Julien F; Di Polo A
    Optom Vis Sci; 2008 Jun; 85(6):417-24. PubMed ID: 18521011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Status and perspectives of neuroprotective therapies in glaucoma: the European Glaucoma Society White Paper.
    Tamm ER; Schmetterer L; Grehn F
    Cell Tissue Res; 2013 Aug; 353(2):347-54. PubMed ID: 23712457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. History of neuroprotection and rationale as a therapy for glaucoma.
    Levin LA; Peeples P
    Am J Manag Care; 2008 Feb; 14(1 Suppl):S11-4. PubMed ID: 18284310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glaucoma: neuroprotection with NAD-based therapeutic interventions.
    Chiarugi A
    Trends Pharmacol Sci; 2023 Dec; 44(12):869-879. PubMed ID: 37880000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.